Q-omics provides the consensus-scored RPL39P40 profile across patient tissues and cancer cell-line models. RPL39P40 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPL39P40 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RPL39P40 RNA expression shows 12,312 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, COAD, and BRCA as cancer lineages where RPL39P40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL39P40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL39P40 survival associations across molecular data types. RPL39P40 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL39P40 RNA expression–survival associations across cancer types. High RPL39P40 expression shows unfavorable associations in CHOL, but favorable associations in STAD, UVM, UCEC, MESO and KIRP. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify STAD as the clearest survival context for RPL39P40 RNA expression.
This table summarizes RPL39P40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RPL39P40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL39P40 shows lower tumor expression in KICH, THCA, BRCA and LUAD and higher tumor expression in COAD and HNSC. The COAD box plot shows higher RPL39P40 RNA expression in tumor versus normal tissue (log2 FC = +1.763, t-test p < 0.001).
This table shows molecular features associated with RPL39P40 in patient tissues and cancer cell lines. In patient samples, RPL39P40 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
